Fig. 2.
Survival according to the current KONOS status and MELD subgroups. 3-months survival of Status 2A was 70.2% (A). However, among Status 2A patients, 78 patients with MELD≤24 showed better survival than current Status 2B group (B). Furthermore, patients with high MELD (≥31) among Status 2B group showed poorer survivals (48.2% of 3-month survival) than current Status 2A group (C).